［1］Chen JH，Liao F，Zhang Y，et al.3D MRI for quantitative analysis of quadrant percent breast density：Correlation with quadrant location of breast cancer［J］.Acad Radiol，2017，42(6)：78-80.
［2］Jafari SH，Saadatpour Z，Salmaninejad A，et al.Breast cancer diagnosis：Imaging techniques and biochemical markers［J］.Cell Physiol，2018，233(7)：5200-5213.
［3］Banaie M，Soltanian-Zadeh H，Saligheh-Rad HR，et al.Spatiotemporal features of DCE-MRI for breast cancer diagnosis［J］.Comput Methods Programs Biomed，2018，155(153)：153-164.
［4］Spak DA，Plaxco JS，Santiago L，et al.BI-RADS fifth edition：A summary of changes［J］.Diagn Interv Imaging，2017，98(3)：179-190.
［5］Greenwood HI，Freimanis RI，Carpentier BM，et al.Clinical breast magnetic resonance imaging：Technique，indications，and future applications［J］.Semin Ultrasound CT MR，2018，39(1)：45-59.
［6］Hammersley JA，Partridge SC，Blitzer GC，et al.Management of high-risk breast lesions found on mammogram or ultrasound：The value of contrast-enhanced MRI to exclude malignanc［J］.Clin Imaging，2018，49：174-180.
［7］Liu L，Yin B，Shek K，et al.Role of quantitative analysis of T2 relaxation time in differentiating benign from malignant breast lesions［J］.Int Med Res，2018，46(5)：1928-1935.
［8］Kanao S，Kataoka M，Iima M，et al.Differentiating benign and malignant inflammatory breast lesions：Value of T2 weighted and diffusion weighted MR images［J］.Magn Reson Imaging，2018，50：38-44.
［9］Kim KW，Kuzmiak CM，Kim YJ，et al.Diagnostic usefulness of combination of diffusion-weighted imaging and T2WI，including apparent diffusion coefficient in breast lesions：assessment of histologic grade［J］.Acad Radiol，2018，25(5)：643-652.
［10］Radhakrishna S，Agarwal S，Parikh PM，et al.3 ole of magnetic resonance imaging in breast cancer management［J］.South Asian J Cancer，2018，7(2)：69-71.
［11］Han XW，Li JF，Chang HY，et al.The value of multi-parameter differential diagnosis of benign and malignant breast lesions by dynamic contrast-enhanced MR imaging and diffusion-weighted imaging［J］.Chinese Journal of Clinicians (Electronic Edition)，2016，10(2)：294-297.［韩小伟，李俊峰，常海艳，等.磁共振动态增强与弥散加权成像多参数鉴别乳腺良恶性病变的诊断价值［J］.中华临床医师杂志(电子版)，2016，10(2)：294-297.］
［12］Surov A，Meyer HJ，Wienke A，et al.Associations between apparent diffusion coefficient (ADC)and KI 67 in different tumors：A meta-analysis.Part 1：ADCmean［J］.Oncotarget，2017，8(43)：75434-75444.
［13］Choi JH，Lim I，Noh WC，et al.Prediction of tumor differentiation using sequential PET/CT and MRI in patients with breast cancer［J］.Ann Nucl Med，2018.doi：10.1007/s12149-018-1259-1257.
［14］Chai RM，Wang X，Huang DS，et al.DWI evaluates the biological characteristics of breast invasive ductal carcinoma［J］.Chinese Medical Imaging Technology，2017，33(8)：1232-1236.［柴瑞梅，王欣，黄德生，等.DWI评价乳腺浸润性导管癌生物学特征［J］.中国医学影像技术，2017，33(8)：1232-1236.］
［15］Horvat JV，Durando M，Milans S，et al.Apparent diffusion coefficient mapping using diffusion-weighted MRI：Impact of background parenchymal enhancement，amount of fibroglandular tissue and menopausal status on breast cancer diagnosis［J］.Eur Radiol，2018，28(6)：2516-2524.
［16］Rabasco P，Caivano P，Simeon V，et al.Can diffusion-weighted imaging and related apparent diffusion coefficient be a prognostic value in women with breast cancer［J］?Cancer Investigation，2017，35(2)：92-99.
［17］Wan CW，Lee CY，Lui CY，et al.Apparent diffusion coefficient in differentiation between malignant and benign breast masses：Does size matter［J］? Clin Radiol，2016，71(2)：170-177.
［18］Park SH，Choi HY，Hahn SY.Correlations between apparent diffusion coefficient values of invasive ductal carcinoma and pathologic factors on diffusion-weighted MRIat 3.0Tesla［J］.Magn Reson Imaging，2015，41(1)：175-182.
［19］Pinker K，Moy L，Sutton EJ，et al.Diffusion-weighted imaging with apparent diffusion coefficient mapping for breast cancerdetection as a stand-alone parameter：Comparison with dynamic contrast-enhanced and multiparametric magnetic resonance imaging［J］.Invest Radiol，2018.doi:10.1097/RLI.0000000000000465.
［20］Shin JK，Kim JY.Dynamic contrast-enhanced and diffusion-weighted MRI of estrogen receptor-positive invasive breast cancers：Associations between quantitative MR parameters and Ki-67 proliferation status［J］.Magn Reson Imaging，2017，45(1)：94-102.
［21］Kong E，Chun KA，Bae YK，et al.Integrated PET/MR mammography for quantitative analysis and correlation to prognostic factors of invasive ductal carcinoma［J］.Nucl Med Mol Imaging，2018，62(1)：118-126.
［22］Le Bihan D，Breton E，Lallemand D，et al.MR imaging of intravoxel incoherent motions：Application to diffusion and perfusion in neurologic disorders［J］.Radiology，1986，161(2)：401-407.
［23］Kim Y，Kim SH，Lee HW，et al.Intravoxel incoherent motion diffusion-weighted MRI for predicting response to neoadjuvant chemotherapy in breast cancer［J］.Magn Reson Imaging，2018，48：27-33.
［24］Wang Q，Guo Y，Zhang J，et al.Contribution of IVIM to conventional dynamic contrast-enhanced and diffusion-weighted MRI in differentiating benign from malignant breast masses［J］.Breast Care (Basel)，2016，11(4)：254-258.
［25］BokachevaL，Kaplan JB，Giri DD，et al.Intravoxel incoherent motiondiffusion-weighted MRI at 3.0T differentiates malignant breast lesions frombenign lesions and breast parenchyma［J］.Journal of Magnetic Resonance Imaging，2013，40(4)：813-823.
［26］He J，Zhang Y，Cheng JL，et al.Single and double index model diffusion-weighted imaging differential diagnosis of benign and malignant breast lesions［J］.Chinese Journal of Medical Imaging，2014，22(1)：30-33.［何杰，张焱，程敬亮，等.单、双指数模型扩散加权成像鉴别诊断乳腺良恶性病变的对比研究［J］.中国医学影像学杂志，2014，22(1)：30-33.］
［27］Zhou WP.Clinical study on the value of IVIM combined with DKI in the diagnosis of dynamic MR enhancement of type I and type II lesions in breast［D］.Suzhou University，2016:1-72.［周卫平，IVIM联合DKI对乳腺MR动态增强Ⅰ型和Ⅱ型病灶诊断价值的临床研究［D］.苏州大学，2016:1-72.］
［28］Bokacheva L，Kaplan JB，Giri DD，et al.Intravoxel incoherent motion diffusion-weighted MRI at 3.0 T differentiates malignant breast lesions from benign 1esions and breast parenchyma［J］.Journal of Magnetic Resonance Imaging，2014，40(4)：813-823.
［29］Kawashima H，Miyati T，Ohno N，et al.Differentiation between luminal-A and luminal-B breast cancer using intravoxel incoherent motion and dynamic contrast-enhanced magnetic resonance imaging［J］.Acad Radiol，2017，24(12)：1575-1581.
［30］Nogueira L，Brandao S，Matos E，et al.Application of the diffusion kurtosis model for the study of breast lesions［J］.Eur Radiol，2014，24(6)：1197-1203.
［31］Li T，Yu T，Li L，et al.Use of diffusion kurtosis imaging and quantitative dynamic contrast-enhanced MRI for the differentiation of breast tumors［J］.Magn Reson Imaging，2018.doi：10.1002/jmri.26059.
［32］Sun K，Chen X，Chai W，et al.Breast cancer：Diffusion kurtosis MR imaging-diagnostic accuracy and correlation with clinical-pathologic factors［J］.Radiol，2015，277(1)：46-55.
［33］Etxano J，Insausti LP，Elizalde A，et al.Analysis of the changes induced by bevacizumab using a high temporal resolution DCE-MRI as prognostic factors for response to further neoadjuvant chemotherapy［J］.Acta Radiol，2015，56(11)：1300-1307.
［34］Xu T，Zhang L，Xu H，et al.Prediction of low-risk breast cancer using quantitative DCE-MRI and its pathological basis［J］.Oncotarget，2017，8(69)：114360-114370.
［35］Kostopoulos SA，Vassiou KG，Lavdas EN，et al.Computer-based automated estimation of breast vascularity and correlation with breast cancer in DCE-MRI images［J］.Magn Reson Imaging，2017，35(1)：39-45.
［36］Boria F，Tagliati C，Baldassarre S，et al.Morphological MR features and quantitative ADC evaluation in invasive breast cancer：Correlation with prognostic factors［J］.Clin Imaging，2018，50：141-146.
［37］Hu CC，Chang TH，Hsu HH，et al.T1-weighted dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)to distinguish between concurrent cholesterol granuloma and invasive ductal carcinoma of the breast：a case report［J］.Am J Case Rep，2018，23(19)：593-598.
［38］Jena A，Taneja S，Singh A，et al.Role of pharmacokinetic parameters derived with high temporal resolution DCE MRI using simultaneous PET/MRI system in breast cancer：A feasibility study［J］.European Journal of Radiology，2018，86：261-266.
［39］Sasaki M，Tozaki M，Kubota K，et al.Simultaneous whole-body and breast 18F-FDG PET/MRI examinations in patients with breast cancer：a comparison of apparent diffusion coefficients and maximum standardized uptake values［J］.Jpn J Radiol，2018，36(2)：122-133.
［40］Plecha DM，Faulhaber P.PET-MRI of the breast［J］.Eur J Radiol，2017，94(17)：A26-A34.
［41］Maria J，Garcia-Velloso，MJ Ribelles，et al.MRI fused with prone FDG PET/CT improves the primary tumour staging of patients with breast cancer［J］.Euro J Radiol，2017，27(8)：3190-3198.